Media headlines about Thoratec (NASDAQ:THOR) have trended somewhat negative this week, Accern Sentiment reports. The research group scores the sentiment of press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Thoratec earned a news sentiment score of -0.12 on Accern’s scale. Accern also gave media headlines about the medical instruments supplier an impact score of 46.0390641515716 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

These are some of the media headlines that may have effected Accern Sentiment Analysis’s scoring:

Thoratec (NASDAQ THOR) remained flat at $63.50 during trading on Tuesday. Thoratec has a 52 week low of $25.04 and a 52 week high of $63.51. The stock’s 50-day moving average price is $63.03 and its 200-day moving average price is $51.62.

WARNING: This news story was posted by Watch List News and is the property of of Watch List News. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark and copyright legislation. The original version of this news story can be read at https://www.watchlistnews.com/thoratec-thor-getting-somewhat-negative-media-coverage-report-finds/1491902.html.

Thoratec Company Profile

Thoratec Corporation develops, manufactures and markets medical devices used for mechanical circulatory support for the treatment of heart failure patients. The Company’s products include ventricular assist devices (VADs), such as HeartMate II Left Ventricular Assist System (HeartMate II), HeartMate III Left Ventricular Assist System, Thoratec Paracorporeal Ventricular Assist Device (PVAD) and Thoratec Implantable Ventricular Assist Device (IVAD).

Receive News & Ratings for Thoratec Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thoratec Co. and related companies with Analyst Ratings Network's FREE daily email newsletter.